PulseMedica Corp.

PulseMedica Corp. , based in Canada, focuses on developing innovative imaging and treatment technologies for vitreoretinal diseases, particularly targeting symptomatic vitreous opacities, also known as eye floaters. Founded in 2018, PulseMedica Corp. is engaged in creating advanced medical technologies for eye care.

The company is headquartered in Edmonton, Canada. It has successfully completed a total of 3 deals, with the most recent funding round occurring on July 16, 2024, where it raised CAD 12 million in PRE-SERIES A funding led by Saltagen Ventures and included investors such as Yaletown Partners and Innovation Fund. The CEO and Founder, Nir Katchinskiy, has a history of involvement in the healthcare technology sector. PulseMedica specializes in developing groundbreaking imaging and treatment technologies for vitreoretinal diseases.

Its core offerings include a high-resolution real-time imaging system, advanced laser technology for improved accuracy and safety, and an automated treatment and planning tool that facilitates image-guided laser treatments. These innovations aim to provide patients with non-invasive solutions for conditions such as vitreous floaters, diabetic retinopathy, and age-related macular degeneration. PulseMedica generates revenue through direct transactions with healthcare providers and ophthalmology clinics, operating a B2B model. Their technologies are available through partnerships with medical institutions, involving sales agreements and service contracts that facilitate the integration of its solutions into clinical practices.

While specific pricing details are not disclosed, the company's offerings are positioned to meet the substantial unmet medical needs in the field of vitreoretinal disease treatment. Following the most recent funding round on July 16, 2024, where PulseMedica raised CAD 12 million, the company plans to utilize these funds to propel preclinical and clinical studies of its floater imaging device, along with conducting laser safety and feasibility studies for upcoming clinical trials. Additionally, PulseMedica aims to strengthen its technical and business teams to support commercialization and regulatory efforts, with a focus on expanding its reach into new geographic markets.